Literature DB >> 9786437

The expression of murine B cell CD23, in vivo, is regulated by its ligand, IgE.

A B Kisselgof1, H C Oettgen.   

Abstract

CD23, the low-affinity IgE receptor, is believed to participate in immune responses by mediating antigen capture for presentation by B cells and by shedding fragments with immunomodulatory properties. The number of CD23 molecules on B cells is increased during allergic responses and infection with helminths. This can be attributed in part to regulation of CD23 expression by cytokines, including IL-4. In addition, there is evidence that CD23 can be induced on cultured B cells by its ligand, IgE. In the current study we use IgE-deficient (IgE-/-) mice to establish the effects of IgE on CD23 expression by B cells in vivo, in the absence of allergic or parasitic stimuli. The spleens of IgE-/- and wild-type mice contained similar proportions of CD23+ B lymphocytes. However, cells from IgE-/- mice were found to have nearly 3-fold less CD23 on their surface. The mutant B cells had a corresponding defect in their ability to bind IgE. CD23 could be normally induced on IgE-/- B cells after culture with IL-4 or CD40 ligand, indicating that these cells had no inherent defect in CD23 biosynthesis. CD23 expression and IgE-binding capacity were both restored when splenocytes from IgE-/- mice were cultured in the presence of IgE. IgE-induced up-regulation of CD23 could be elicited in vivo as well. In IgE-/- mice, i.v. infusion of IgE corrected CD23 expression to wild-type levels. Our results demonstrate that IgE directly participates in CD23 regulation in vivo. This positive feedback loop may constitute a mechanism for the amplification of ongoing allergic responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9786437     DOI: 10.1093/intimm/10.9.1377

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  14 in total

Review 1.  IgE in asthma and atopy: cellular and molecular connections.

Authors:  H C Oettgen; R S Geha
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 2.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 3.  Omalizumab: a monoclonal anti-IgE antibody.

Authors:  Paul P Belliveau
Journal:  MedGenMed       Date:  2005-01-27

Review 4.  Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases.

Authors:  Oliver T Burton; Hans C Oettgen
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

5.  Differential regulation of a family of apyrase genes from Medicago truncatula.

Authors:  J R Cohn; T Uhm; S Ramu; Y W Nam; D J Kim; R V Penmetsa; T C Wood; R L Denny; N D Young; D R Cook; G Stacey
Journal:  Plant Physiol       Date:  2001-04       Impact factor: 8.340

Review 6.  Omalizumab in asthma: approval and postapproval experience.

Authors:  Dean T Chiang; Justin Clark; Thomas B Casale
Journal:  Clin Rev Allergy Immunol       Date:  2005-08       Impact factor: 8.667

7.  Allergen-independent immunomodulatory activities of immunoglobulin E.

Authors:  A A Horner; T Kawakami
Journal:  Clin Exp Allergy       Date:  2009-01-22       Impact factor: 5.018

Review 8.  Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases.

Authors:  Hans C Oettgen
Journal:  J Allergy Clin Immunol       Date:  2016-06       Impact factor: 10.793

Review 9.  Antigen-independent effects of immunoglobulin E.

Authors:  Paul J Bryce; Hans C Oettgen
Journal:  Curr Allergy Asthma Rep       Date:  2005-05       Impact factor: 4.919

10.  Helminth-induced CD19+CD23hi B cells modulate experimental allergic and autoimmune inflammation.

Authors:  Mark S Wilson; Matthew D Taylor; Mary T O'Gorman; Adam Balic; Tom A Barr; Kara Filbey; Stephen M Anderton; Rick M Maizels
Journal:  Eur J Immunol       Date:  2010-06       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.